Pharma International Company (PIC) is a leading biopharmaceutical corporation dedicated to developing, manufacturing and commercializing quality branded generic medications that improve health outcomes, cost of care and the wellbeing of patients across the Middle East and Africa (MEA).
Since our establishment in Jordan in 1994, we have cultivated a thriving culture of innovation, amply demonstrated by the depth and breadth of our product portfolio of over 200 products spanning across key therapeutic classes, including Anti-infectives, Nervous System, Respiratory System, Cardio Vascular and Lifestyle conditions. Our relentless focus on quality and the wellbeing of patients we touch the lives of has allowed us to emerge as one of the fastest growing companies in Saudi Arabia, Iraq and Jordan, and enjoys an enviable market presence in over 25 markets across the Levant, the GCC, Africa and parts of Eastern Europe.
Our success over the years has led Al Faisaliah Group, one of Saudi Arabia's top 20 and fastest-growing conglomerates operating across the Middle East, to acquire a majority share in PIC in 2014, setting us on track to tripling our revenue by 2020 and covering most of the MEA region.
Today, PIC is uniquely positioned to become as the Biopharmaceutical Partner of Choice to key healthcare stakeholders across emerging markets, including patients, regulators, payers and customers.To watch our video
PIC operates two globally-accredited, state-of-the-art manufacturing facilities outfitted with fully-computerized machinery and compliant with major regulatory agencies. We have been certified by the Irish Medicines Board; are GMP certified in Ireland, Ukraine, Jordan, Iraq, the GCC, Sudan, Tanzania and Chad; and are ISO 9001-14001 and ISO 18001 compliant.
Our main plant, licensed in 2000 by the Jordan Ministry of Health, covers a total area of around 9,300 m2 and is equipped to produce the following dosage forms:
In turn, our segregated cephalosporin manufacturing plant, established in 2012 as one of the few such facilities in the region, covers a total area of 5,000 m2 and is equipped to produce the following dosage forms:
Since our establishment in 1994, our fast-paced growth in providing quality products in MENA region was made possible through diligence of our people and trust in our partners. We have learnt, throughout these years, to cherish our partners and recognize their contribution to our success. This philosophy, together with our adherence to our values, helped us gain a reputation of ethical business practice which resulted in building long lasting, mutually beneficial alliances.
PIC has been providing support to facilitate our partners’ access to MENA market through our expertise in the domains of regulatory affairs, supply chain, R&D, production, quality, and marketing; which enable us to craft our strategic actions with precision, and implement them with confidence to reach our mutual goals.
Our brand image has become well-known in the region and trusted by healthcare professionals in different specialties; as we provide a wide range of products covering several therapeutic areas.
Our mission is to expand our product portfolio by in-licensing high quality pharmaceutical products from qualified partners who share our values.
Our strategy is to grow our portfolio in certain therapy areas including cardiovascular and diabetes, GIT, anti-infectives, CNS and specialty/hospital products. We’re also developing our presence in oncology, respiratory and biosimilars. We seek “normal” generics as well as difficult-to-make generics, differentiated products and value-added medicine.
We welcome new ideas and are keen for innovation. We are flexible with our business models and have been operating under several forms of collaboration. Pharmaceuticals innovators and generic developers are invited to contact us and present their strengths. Our undertaking is to evaluate each opportunity individually and thoroughly.